Erratum: Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs (Blood Advances (2017) 1:25 (2329-2342) DOI: 10.1182/bloodadvances.2017011411)
© 2018 by The American Society of Hematology. On page 2339, under "Authorship," the contribution paragraph should have read, "J.R.F., D.E.Z., G.A., and R.A.S. conceived the study and wrote the paper; E.S., N.M.V., P.M., E.D.G., S.W.B., P.S., M.S., S.J., A.S., and D.T.O. developed the vaccine formulations; J.R.F., C.L., N.L.Y., B.G., B.J.F., M. Ackerman, M. Alam, G.F., and G.D.T. designed and carried out experiments; C.J. and D.E.Z. performed the transcriptional analyses; M.J. performed half-life modeling; and A.A., D.E.Z., G.A., and R.A.S. gave conceptual advice and project oversight." The conflict-of-interest paragraph under "Authorship" should have read, "E.S., N.M.V., P.M., E.D.G., S.W.B., P.S., M.S., S.J., and D.T.O. were employees of Novartis Vaccines at this study's conception. A.S. is the chief executive officer and chief science officer of and owns stock in Oncovir, Inc, the company that makes pIC:LC (Hiltonol). The remaining authors declare no competing financial interests." The errors have been corrected in the published article.
Francica, JR; Zak, DE; Linde, C; Siena, E; Johnson, C; Juraska, M; Yates, NL; Gunn, B; De Gregorio, E; Flynn, BJ; Valiante, NM; Malyala, P; Barnett, SW; Sarkar, P; Singh, M; Jain, S; Ackerman, M; Alam, M; Ferrari, G; Salazar, A; Tomaras, GD; O'Hagan, DT; Aderem, A; Alter, G; Seder, RA
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)